Parabilis Medicines vs athenahealth
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline
About
Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.
$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025
About
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.